NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates

Financial Performance - NeuroPace, Inc. reported a quarterly loss of $0.19 per share, better than the Zacks Consensus Estimate of a loss of$ 0.26, and an improvement from a loss of $0.28 per share a year ago, representing an earnings surprise of 26.92% [1] - The company posted revenues of$ 21.06 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 8.95%, and up from $16.43 million in the same quarter last year [2] - Over the last four quarters, NeuroPace has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - NeuroPace shares have declined approximately 29.4% since the beginning of the year, contrasting with the S&P 500's gain of 25.8% [3] - The current Zacks Rank for NeuroPace is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$ 0.25 on revenues of $20.54 million, and for the current fiscal year, it is -$ 1.08 on revenues of $77.25 million [7] - The estimate revisions trend for NeuroPace is mixed, and future changes in estimates will be closely monitored following the recent earnings report [6][7] Industry Context - NeuroPace operates within the Medical - Instruments industry, which is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - The performance of NeuroPace's stock may be influenced by the overall outlook for the industry [8]